Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression

The high incidence of resistance to Tyrosine Kinase Inhibitors (TKIs) targeted against EGFR and downstream pathways has increased the necessity to identify agents that may be combined with these therapies to provide a sustained response for breast cancer patients. Here, we investigate the therapeuti...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Cancer
Prif Awduron: Suárez-Arroyo, Ivette J., Rios-Fuller, Tiffany J., Feliz-Mosquea, Yismeilin R., Lacourt-Ventura, Mercedes, Leal-Alviarez, Daniel J., Maldonado-Martinez, Gerónimo, Cubano, Luis A., Martínez-Montemayor, Michelle M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Ivyspring International Publisher 2016
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4780125/
https://ncbi.nlm.nih.gov/pubmed/26958085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.13599
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg